Lianbio (LIANY) Stock Price & Analysis
Lianbio (LIANY) rose 0.09% to USD 0.11 as of June 10, 2026 at 15:07 UTC, according to Nexqual real-time market data.
LIANY last closed at USD 0.11; the session ranged USD 0.11–0.11 on volume of 59 shares. Market capitalization is $12.04M, with a 52-week range of USD 0.03–0.44 (PNK). Source: Nexqual, June 10, 2026 at 15:07 UTC.
Key Statistics (as of June 10, 2026 at 15:07 UTC)
| Price | USD 0.11 |
|---|---|
| Change | ▲ 0.09% (up) |
| Previous Close | USD 0.11 |
| Open | USD 0.11 |
| Day Range | USD 0.11 – 0.11 |
| 52-Week Range | USD 0.03 – 0.44 |
| Volume | 59 shares |
| Market Cap | $12.04M |
| Exchange | PNK |
Technical Analysis (LIANY)
Nexqual's technical model rates LIANY "BUY" based on 5 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 15:07 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.93 (neutral) |
| vs SMA50 | Below (USD 0.13) |
| MACD | 0.01 (positive) |
Analyst Ratings (LIANY)
Wall Street analysts rate LIANY "None", per Nexqual as of June 10, 2026 at 15:07 UTC.
| Consensus Rating | None |
|---|
Earnings (LIANY)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -0.22 vs est -0.33 ▲ beat |
| 2023-06-30 | USD -0.2 vs est -0.29 ▲ beat |
| 2023-03-31 | USD -0.22 vs est -0.27 ▲ beat |
| 2022-12-31 | USD -0.17 vs est -0.25 ▲ beat |
Source: Nexqual, June 10, 2026 at 15:07 UTC.
Financials & Fundamentals (LIANY)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -32.42% |
| Debt / Equity | 1.2 |
| Current Ratio | 10.06 |
| Total Cash | $252.22M |
| Total Debt | $2.84M |
| Free Cash Flow | $-36.86M |
Source: Nexqual, June 10, 2026 at 15:07 UTC.
Financial Health Score (LIANY)
Nexqual rates Lianbio's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 15:07 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $252M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$84M |
| Efficiency | Critical — ROE -32%, ROA -21.7% |
Ownership (LIANY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +7.46% |
| Shares Outstanding | 109.13M |
| Float | 107.65M |
| Short % of Float | +0.83% |
Source: Nexqual, June 10, 2026 at 15:07 UTC.
Leadership (LIANY)
Lianbio is led by Adam Leo Stone (age 45), Interim CEO & Director, per Nexqual as of June 10, 2026 at 15:07 UTC.
| Interim CEO & Director | Adam Leo Stone (age 45) |
|---|---|
| Founder & Executive Chairman | Konstantin Poukalov (age 41) |
| Interim CFO, VP & Head of Global Finance | Ehong Gu |
Major Backers & Investors (LIANY)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.57% |
Source: Nexqual, June 10, 2026 at 15:07 UTC.
From Lianbio's Latest SEC 10-K Filing (filed 2023-03-28)
Key Strengths & Strategy (as disclosed to the SEC)
- We estimate there are approximately 1.1 million to 2.8 million HCM patients in China, with approximately two-thirds of patients having oHCM, and one-third of patients having nHCM.
- Tarsus submitted a New Drug Application ("NDA") to the FDA, with a target action date for the Prescription Drug User Fee Act ("PDUFA") of August 25, 2023.
- With operations in China, Asia Pacific, and the United States, we have built a cross-border platform to provide our licensing partners access to our regulatory, development, and commercial expertise in China and other Asian markets.
- We believe that enrolling patients in China in a global Phase 3 clinical trial may expedite the global development program as well as enable us to seek regulatory approval in China.
Partnerships
- Our pipeline Cardiovascular Mavacamten for the potential treatment of HCM We have partnered with MyoKardia, Inc. ("MyoKardia," now a wholly owned subsidiary of Bristol-Myers Squibb ("BMS")) to develop and commercialize mavacamten in Greater China and other Asian markets.
- Ophthalmology TP-03 for the potential treatment of demodex blepharitis and meibomian gland disease We have partnered with Tarsus Pharmaceuticals, Inc. ("Tarsus") to develop and commercialize TP-03 (lotilaner ophthalmic solution, 0.25%) in Greater China.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CFRXQ | ContraFect Corporation | USD 0 | ▲ 0% |
| ATHXQ | Athersys, Inc. | USD 0 | ▲ 0% |
| BTVRF | BLUERUSH INC. | USD 0 | ▲ 0% |
| ASAPQ | Waitr Holdings Inc. | USD 0 | ▲ 0% |
| EESE | Energy & Environmental Services | USD 0.09 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 15:07 UTC. This page is informational and not investment advice.